pharma · Social Anxiety Disorder · Drug Drug Interaction · VTGN
Vistagen Therapeutics
Vistagen Therapeutics patent portfolio — 6 USPTO pharmaceutical patents (A61K/A61P) with grant dates, status, and loss-of-exclusivity filters.
Company details
- Status
- Public
- HQ
- Cambridge, USA
- Employees
- 7
- Programs
- 10
- Drugs
- 3
- Patents
- 6
Vistagen Therapeutics patents
6 pharmaceutical patents indexed for Vistagen Therapeutics. 0 expire within 24 months.
Vistagen Therapeutics has 6 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 0 expire within 24 months — use filters for patent-cliff planning.
Patent portfolio
-
US 12036198
Dosage forms and therapeutic uses of L-4-chlorokynurenine
granted -
US 10980758
Dosage forms and therapeutic uses of L-4-chlorokynurenine
granted -
US 10632091
Dosage forms and therapeutic uses of L-4-chlorokynurenine
granted -
US 10617663
Dosage forms and therapeutic uses of L-4-chlorokynurenine
granted -
US 9993453
Dosage forms and therapeutic uses L-4-chlorokynurenine
granted -
US 9993450
Dosage forms and therapeutic uses of L-4-chlorokynurenine
granted
Frequently asked questions
How many patents does Vistagen Therapeutics have?
6 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do Vistagen Therapeutics patents expire?
0 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.